OS
Figure 1 · Panel E
Panel E 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Francesco Sanvito, Catalina Raymond, Donatello Telesca, Jingwen Yao, Lauren E Abrey, Josep Garcia, Brian Simmons, Olivier Chinot, Frank Saran, Ryo Nishikawa, Roger Henriksson, Warren P Mason, Wolfgang Wick, Timothy F Cloughesy, Benjamin M Ellingson
Clin Cancer Res 32(11) 2230-2242
PURPOSE: Brain tumor location is known to affect survival, but there is a lack of methodologic tools for systematically studying the complex interplay between brain tumor location, prognostic variables, treatment schemes, and survival. EXPERIMENTAL DESIGN: A total of 592 prospectively enrolled patients with newly diagnosed glioblastoma from the phase III AVAglio trial, randomized to postsurgical chemoradiation with or without bevacizumab, were retrospectively analyzed. Statistical parametric mapping was conducted with multivariate Cox proportional hazards models at the voxel-wise level, incorporating dedicated interaction variables to evaluate the impact of baseline tumor volume and treatment arm on survival for different tumor locations from magnetic resonance imaging (MRI) scans, with subsequent cluster-based correction for multiple testing and mathematical estimation of regional survival curves. RESULTS: Tumor location in the right prefrontal cortex was an independent favorable prognostic factor [median hazard ratio (HR) = 0.57] for survival, whereas tumor involvement in left hemisphere eloquent areas with language and visual functions was unfavorable (median HR = 1.69). Larger presurgical tumor volumes were associated with shorter survival independent of tumor location (HR = 1.005), but the effect was larger for tumor locations including eloquent structures (HR ranging 1.008-1.015), whereas nonsignificant for anterior frontal locations. Bevacizumab seemed to grant a survival benefit when specific brain regions were involved or spared by the tumor, but this result was not confirmed after correction for multiple testing. CONCLUSIONS: This workflow allows to map the survival effects of variables onto specific brain tumor locations, revealing location dependency of prognostic variables such as tumor volume, and potentially of treatment schemes, with relevant implications in risk stratification and clinical management.
5 个 Figure · 11 个 KM 面板
Figure 1. Workflow for SPM with voxel-wise multivariate Cox models. Voxel-wise multivariate models were run by including voxel-specific covariates ( A ), and the HR for the effect coefficient of the covariate of interest was mapped voxel-wise to visualize the uncorrected SPM ( B ). Permutation testing was used for multiple testing correction ( C ) to select the clusters more likely to represent true-positive results ( D ). Modeled survival curves were calculated using the regional effect coefficients estimated by the models by imposing the desired hypothetical values of the covariates of interest ( E ).
Figure 1 · Panel E
Panel E 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2. Impact of voxel-wise tumor location on survival ( tumor presence in model 3). Anterior right frontal locations are associated with a longer survival (cluster I, violet-blue), whereas numerous other locations in the left hemisphere are associated with a shorter survival (cluster II, red-orange; A and B , only regions with P < 0.05 and surviving multiple testing correction). Prognostic differences can be visualized by plotting HR ( C and E ) and displaying modeled survival curves ( D and F ) corresponding to the clusters and to specific representative brain regions of interest, respectively. L, left; R, right; WM, white matter.
Figure 2 · Panel D
Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel F
Panel F 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. Impact of tumor volume on survival for different voxel-wise tumor locations ( volume | tumor presence in model 4 ). In numerous bilateral hemispheric tumor locations (cluster III, orange-yellow in A ), a larger tumor volume was associated with shorter survival, whereas it was not a significant predictor in other regions, such as bilateral anterior frontal areas. Notably, the effect size of tumor volume in cluster III (orange in B ) was larger than tumor volume independent of tumor location (dashed line in B ) and larger than tumor volume in regions outside cluster III (dotted line in B ). This difference can be also visualized by comparing modeled survival curves for different hypothetical tumor volumes with localization in cluster III ( C ) and outside cluster III ( D ) and by comparing specific representative regions belonging to cluster III ( E and F ) and outside cluster III ( G ). cc, cubic centimeters; L, left; R, right.
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel D
Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel E
Panel E 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel F
Panel F 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel G
Panel G 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. Impact of treatment arm on survival for different voxel-wise tumor locations ( Tx | tumor presence in model 5). For tumor location in some superficial cortical regions, mainly in the left hemisphere (blue clusters in A ), the experimental treatment arm chemoradiation + bevacizumab was associated with longer survival, as also evident from the histogram plots of HR values (blue in B ) and the modeled survival curves (blue in C ). Conversely, for tumor location in some right hemisphere regions, including the precentral gyrus and some deep-seated areas (yellow-red clusters in A ), the experimental treatment arm was associated with shorter survival (orange histograms in B and modeled survival curves in D ). However, these results did not survive the correction for multiple testing and may represent false-positive results. Bev, bevacizumab; ChemoRT, chemoradiation; L, left; R, right.
Figure 4 · Panel C
Panel C 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel D
Panel D 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5. Impact of treatment arm on survival for regions spared by tumor location ( Tx | tumor absence in model 5). The experimental treatment arm chemoradiation + bevacizumab was associated with longer survival when tumors spared specific brain regions, particularly a large cluster that involves the right pyramidal tract territory and right-hemisphere deep-seated areas (purple in A ), also shown with the histogram plots of HR values (purple in B ) and with the modeled survival curves (purple in C ). However, these results did not survive the correction for multiple testing and may represent false-positive results. Bev, bevacizumab; ChemoRT, chemoradiation; L, left; R, right.
Figure 5 · Panel C
Panel C 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。